Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…
Case report and review of TTMV::RARA-positive APL with spinal cord compression in a child
Doctors treated a boy with rare leukemia and spinal pressure using special drugs
This is a case report with a systematic review of 11 published cases of TTMV::RARA-positive acute promyelocytic leukemia (APL). The authors …
A nine-year-old boy had rare leukemia and spinal cord pressure. Doctors used specific drugs that helped clear the disease and fix his spine.
Review of ATRA and ATO induction therapy in acute promyelocytic leukemia with RNA sequencing insights
Why PCR Missed This Leukemia
This case report and literature review examines induction therapy using all-trans retinoic acid and arsenic trioxide in acute promyelocytic …
A standard blood test missed a dangerous leukemia because the disease had a unique genetic pattern that routine screening overlooked until a…
Phase II trial shows high remission and survival with frontline ATRA-ATO for newly diagnosed APL
Can a chemotherapy-free treatment beat a rare, aggressive leukemia?
A prospective multicenter phase II trial in 81 newly diagnosed APL patients in Japan found that frontline ATRA-ATO therapy achieved a 95.1% …
A chemotherapy-free treatment for acute promyelocytic leukemia achieved 95% remission and 95% survival three years later in a Japanese trial…
AI tool predicts acute leukemia subtypes with AUROC 0.94 for AML, 0.98 for promyelocytic, 0.84 for ALL in international cohort
Can a simple blood test help diagnose leukemia? An AI tool shows promise but still needs work
An AI tool was tested on a retrospective, international cohort of 6206 leukemia patients from 20 centers to predict acute leukemia subtypes …
An AI tool can spot leukemia from standard blood tests but must refuse to guess for most patients until doctors refine it to help more peopl…
Research across Leukemia
Related studies from across the Leukemia family.
AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
7-day venetoclax with intensive chemotherapy achieves 90.3% composite complete remission in AML
Trial shows venetoclax combined with chemotherapy for AML
This clinical trial of 259 newly diagnosed patients with acute myeloid leukemia found a 90.3% composite complete remission rate using a 7-da…
A new clinical trial shows that a short 7-day course of venetoclax combined with chemotherapy can achieve high remission rates in AML patien…
Rate of drug concentration rise alters hemodynamic responses and mortality risk in coronary heart disease patients
New analysis shows how fast drug levels change affects patient safety outcomes
This narrative review and theoretical framework synthesizes evidence on rate-dependent pharmacology. It highlights divergent hemodynamic res…
This review explains that how quickly medicine levels rise in the body matters for safety. Fast changes can cause more harm than slow ones, …
Novel strategies aim to separate GVHD from GVL effects in allo-HCT for AML
Novel strategies aim to separate GVHD from GVL effects in leukemia patients
This narrative review explores novel therapeutic strategies to separate graft-versus-host disease (GVHD) from graft-versus-leukemia (GVL) ef…
A narrative review explores new ways to treat acute myeloid leukemia while managing side effects after stem cell transplants.
HMA-venetoclax yields 50% overall response rate in relapsed/refractory AML meta-analysis
Combination therapy shows response in relapsed leukemia
This systematic review and meta-analysis of 2289 adults with relapsed/refractory acute myeloid leukemia found that hypomethylating agents pl…
For adults with relapsed leukemia, combining two drugs led to a 50% response rate, offering a potential new option for a tough situation.
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients
Review explores antibody therapies for relapsed acute myeloid leukemia
This narrative review examines antibody-based therapies for relapsed or refractory acute myeloid leukemia. The authors discuss potential eff…
A review looks at antibody-based therapies for patients with relapsed acute myeloid leukemia, comparing them to traditional treatment option…
Fertility preservation in female leukemia patients carries risks of leukemic cell contamination and disease reintroduction
Fertility preservation options carry risks for female leukemia patients
This review examines fertility preservation strategies for female patients with leukemia. The authors note that oocyte or embryo cryopreserv…
Fertility preservation strategies for female leukemia patients face safety concerns like disease reintroduction and contamination risks that…
Xatmep receives FDA approval for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis
FDA approves Xatmep for pediatric leukemia and arthritis treatment options
The FDA has approved Xatmep for pediatric patients with acute lymphoblastic leukemia or active polyarticular juvenile idiopathic arthritis. …
The FDA has approved Xatmep to treat specific forms of childhood leukemia and arthritis, offering new options for young patients.
Review of glycolytic metabolism in acute myeloid leukemia cells notes research scope and limitations
Scientists examine how sugar metabolism affects acute myeloid leukemia cells
This narrative review examines glycolytic enzymes and glycolytic metabolism within acute myeloid leukemia (AML) cells. The authors synthesiz…
This review looks at how glycolytic enzymes and metabolism impact acute myeloid leukemia cells, offering new insights into this serious bloo…
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Scoping review examines imatinib gonadotoxicity in males with chronic myeloid leukemia or gastrointestinal stromal tumors
Young Men's Fertility at Risk with Common Cancer Drug Imatinib
This scoping review synthesizes evidence on imatinib effects in males with chronic myeloid leukemia or gastrointestinal stromal tumors. Twen…
• Imatinib harms sperm production more in younger men permanently • Helps doctors counsel teens and young adults before treatment • Not a tr…
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis
A single patient found relief from blood cancer with a new drug combo
This case report and literature review describes a 52-year-old male with connective tissue disease, chronic myelomonocytic leukemia, and mye…
One man with blood cancer saw his fever and anemia improve after two years on a specific drug mix, offering a glimpse into potential new tre…
Questions about Acute Promyelocytic Leukemia
How effective is frontline ATRA-ATO therapy for newly diagnosed Acute Promyelocytic Leukemia?
Frontline ATRA-ATO therapy is highly effective for newly diagnosed APL, with complete remission rates over 94% and 3-year survival above 93% in clinical trials.
Full answer →Does the new AI test work well for distinguishing Acute Promyelocytic Leukemia from other types?
An AI tool shows very high accuracy for distinguishing Acute Promyelocytic Leukemia (APL) from other leukemias, with an AUROC of 0.98 in international tests, though it currently excludes many patients from predictions.
Full answer →What are the survival rates for Acute Promyelocytic Leukemia treated with ATRA and ATO?
ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.
Full answer →